Join us to hear from Nan Chen, MD, researcher and breast medical oncologist at the University of Chicago, as she highlights some of the promising advancements in metastatic breast cancer from the 2026 ASCO Annual Meeting. Dr. Chen will break down key findings, emerging treatments, and what these updates could mean for you. The session will include dedicated time for audience Q&A at the end.
Key Takeaways:
In this analysis of the HER2CLIMB-05 study, we examined additional efficacy outcomes, including PFS, cORR, and DOR, as well as safety outcomes by stratified subgroups.
Tucatinib (TUC) + 1L maintenance therapy with trastuzumab (H) and pertuzumab (P) demonstrated clinically meaningful efficacy vs placebo + HP in patients with HR+ or HR− disease, ± baseline BM, and de novo or recurrent disease, with a similar safety profile seen across subgroups.
Results were consistent with the overall population and support TUC + HP as a potential new maintenance therapy across patients with HER2+ MBC.